Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma
暂无分享,去创建一个
D. Hallahan | Xiaowei Wang | Subhajit Ghosh | D. DeNardo | D. Thotala | F. Frenkel | R. Ataullakhanov | Jiayi Huang | M. Inkman | N. Miheecheva | Jin Zhang | Sukrutha Thotala | E. Tikhonova
[1] S. Mitra,et al. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs , 2021, Cells.
[2] A. S. Booeshaghi,et al. Modular, efficient and constant-memory single-cell RNA-seq preprocessing , 2021, Nature Biotechnology.
[3] D. Gabrilovich,et al. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity , 2021, Nature Reviews Immunology.
[4] J. Bussink,et al. Radiotherapy and cGAS/STING signaling: Impact on MDSCs in the tumor microenvironment. , 2021, Cellular immunology.
[5] M. Weller,et al. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma , 2020, JAMA oncology.
[6] G. Esendagli,et al. Protocol to assess the suppression of T-cell proliferation by human MDSC. , 2020, Methods in enzymology.
[7] J. Campian,et al. Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients , 2019, Journal of Neuro-Oncology.
[8] Jill S Barnholtz-Sloan,et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. , 2018, Neuro-oncology.
[9] B. Nahed,et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors , 2018, Nature Network Boston.
[10] D. Hallahan,et al. Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma. , 2018, International journal of radiation oncology, biology, physics.
[11] Fabian J Theis,et al. SCANPY: large-scale single-cell gene expression data analysis , 2018, Genome Biology.
[12] Weiqun Li,et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment , 2017, Journal of Immunotherapy for Cancer.
[13] R. Weichselbaum,et al. Host STING-dependent MDSC mobilization drives extrinsic radiation resistance , 2017, Nature Communications.
[14] A. Enk,et al. Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe) , 2017, Oncoimmunology.
[15] P. Lowenstein,et al. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[16] Grace X. Y. Zheng,et al. Massively parallel digital transcriptional profiling of single cells , 2016, Nature Communications.
[17] D. Hallahan,et al. Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy , 2017, Journal of Neuro-Oncology.
[18] A. Mangraviti,et al. Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium , 2016, Journal of immunology research.
[19] J. Campian,et al. Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma , 2016, Journal of Neuro-Oncology.
[20] Kristen L. Jones,et al. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model , 2015, Cancer Immunology Research.
[21] D. Hallahan,et al. Stem Cell Transfusion Restores Immune Function in Radiation-Induced Lymphopenic C57BL/6 Mice. , 2015, Cancer research.
[22] G. Linette,et al. Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma. , 2015, International journal of radiation oncology, biology, physics.
[23] I. Hermans,et al. Enhanced immunosuppression by therapy‐exposed glioblastoma multiforme tumor cells , 2015, International journal of cancer.
[24] S. Goodman,et al. Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma , 2015, Clinical Cancer Research.
[25] R. Miralbell,et al. Re: Prophylactic Sildenafil Citrate Improves Select Aspects of Sexual Function in Men Treated with Radiotherapy for Prostate Cancer: Zelefsky J.M. et al , Urol 2014; 192: 868-874 , 2015 .
[26] Wei Zhou,et al. Cytokines: shifting the balance between glioma cells and tumor microenvironment after irradiation , 2015, Journal of Cancer Research and Clinical Oncology.
[27] P. Wen,et al. Immunotherapy advances for glioblastoma. , 2014, Neuro-oncology.
[28] G. Finocchiaro,et al. Perspectives for immunotherapy in glioblastoma treatment , 2014, Current opinion in oncology.
[29] J. Califano,et al. Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma , 2014, Clinical Cancer Research.
[30] M. Zelefsky,et al. Prophylactic sildenafil citrate improves select aspects of sexual function in men treated with radiotherapy for prostate cancer. , 2014, The Journal of urology.
[31] P. Newell,et al. Expression of Arginase I in Myeloid Cells Limits Control of Residual Disease after Radiation Therapy of Tumors in Mice , 2014, Radiation research.
[32] T. Pisansky,et al. Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial. , 2014, JAMA.
[33] K. Hoang-Xuan,et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[34] K. Aldape,et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[35] A. Shindel. Tadalafil for Prevention of Erectile Dysfunction After Radiotherapy for Prostate Cancer: The Radiation Therapy Oncology Group [0831] Randomized Clinical Trial , 2014 .
[36] V. Bronte,et al. Complexity and challenges in defining myeloid-derived suppressor cells. , 2014, Cytometry. Part B, Clinical cytometry.
[37] Walter J Curran,et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] Stephen Mok,et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. , 2013, Cancer research.
[39] M. Sade-Feldman,et al. Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. , 2013, Immunity.
[40] M. Brock,et al. Treatment-related Lymphopenia in Patients With Stage III Non-Small-Cell Lung Cancer , 2013, Cancer investigation.
[41] Lawrence Kleinberg,et al. The Etiology of Treatment-related Lymphopenia in Patients with Malignant Gliomas: Modeling Radiation Dose to Circulating Lymphocytes Explains Clinical Observations and Suggests Methods of Modifying the Impact of Radiation on Immune Cells , 2013, Cancer investigation.
[42] S. Grossman,et al. The Association Between Treatment-Related Lymphopenia and Survival in Newly Diagnosed Patients with Resected Adenocarcinoma of the Pancreas , 2012, Cancer investigation.
[43] B. Kleinschmidt-DeMasters,et al. Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. , 2011, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] D. Schadendorf,et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model , 2011, Proceedings of the National Academy of Sciences.
[45] S. Piantadosi,et al. Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide , 2011, Clinical Cancer Research.
[46] B. Rini,et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. , 2011, Neuro-oncology.
[47] T. Scriba,et al. Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation , 2010, Journal of immunological methods.
[48] S. Ostrand-Rosenberg. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity , 2010, Cancer Immunology, Immunotherapy.
[49] T. Padhya,et al. Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells1 , 2009, The Journal of Immunology.
[50] P. Sinha,et al. Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer 1 , 2009, The Journal of Immunology.
[51] K. Gupta,et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer , 2007, Nature Medicine.
[52] P. Sinha,et al. Prostaglandin E 2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells , 2007 .
[53] J. Califano,et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function , 2006, The Journal of experimental medicine.
[54] S. Segal,et al. CD11b+/Gr-1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1β-Secreting Cells1 , 2005, The Journal of Immunology.
[55] S. Piantadosi. Translational clinical trials: an entropy-based approach to sample size , 2005, Clinical trials.
[56] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[57] J. Brayer,et al. Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses , 2004, Cancer Research.
[58] I. Maclennan,et al. Analysis of treatment in childhood leukemia. IV. The critical association between dose fractionation and immunosuppression induced by cranial irradiation , 1978, Cancer.